Like last year, 2026 appears poised to herald the arrival of multiple mega-blockbusters—albeit on an even grander scale than 2025’s plenty-respectable slate of major rollouts.
According to Evaluate’s annual analysis of the biggest potential drug launches of the coming year, the top 10 most anticipated meds could generate a combined $45.9 billion in annual sales by 2032.
That’s a massive jump from the $29 billion figure that Evaluate calculated for last year’s top 10, which itself was the highest total in years.
In fact, combined sales from the top two drugs on the 2026 list alone are predicted to equal the 2025 total: Novo Nordisk’s CagriSema and Eli Lilly’s orforglipron—both candidates in the perennially hot area of obesity and Type 2 diabetes—are on track to rake in a respective $17.2 billion and $11.8 billion within just a few years, per the analysis.
There’s a steep dropoff from that duo to the remaining eight entries on the 2026 docket, which include meds from the likes of Gilead Sciences, Johnson & Johnson, AstraZeneca and other biopharmas big and small, spanning a range of indications from breast cancer to essential tremor. Predicted 2032 sales for the octet weigh in at a more modest—though still blockbuster-worthy—range of $1.7 billion to $2.5 billion each.
Of course, it remains to be seen not only whether the anointed drugs will reach those lofty sales goals by 2032, but also, more pressingly, whether they’ll secure the anticipated approvals this year so they can begin racking up any sales at all.
On the second point, at least, Evaluate’s crystal ball has recently been particularly clear: An impressive nine of 2025’s top 10 earned their predicted approvals before the end of last year, with the only holdout Sanofi’s multiple sclerosis candidate tolebrutinib, which was rejected by the FDA in the final days of December.
If that accuracy streak stretches to this year’s slate, the industry is in for quite the downpour of high-profile approvals and skyrocketing sales.
Read on for the full list of the top 10 most anticipated drug launches of 2026, and revisit last year’s roundup here.
• CagriSema
Manufacturer: Novo Nordisk
Indications: Obesity and Type 2 Diabetes
Sales Forecast by 2032: $17.2 billion
•Orforglipron
Manufacturer: Eli Lilly
Indications: Obesity and Type 2 Diabetes
Sales Forecast by 2032: $11.8 billion
•Anito-cel
Manufacturer: Gilead Sciences / Arcellx
Indications: Multiple Myeloma
Sales Forecast by 2032: $2.5 billion
•Brepocitinib
Manufacturer: Roivant Sciences
Indications: Dermatomyositis
Sales Forecast by 2032: $2.3 billion
•Icotrokinra
Manufacturer: Johnson & Johnson / Protagonist
Indications: Autoimmune Diseases
Sales Forecast by 2032: $2.2 billion
•Gedatolisib
Manufacturer: Celcuity
Indications: Breast Cancer
Sales Forecast by 2032: $2.1 billion
•Ulixacaltamide
Manufacturer: Praxis Precision Medicines
Indications: Essential Tremor
Sales Forecast by 2032: $2.1 billion
•Baxdrostat
Manufacturer: AstraZeneca
Indications: High Blood Pressure
Sales Forecast by 2032: $2 billion
•Camizestrant
Manufacturer: AstraZeneca
Indications: Hormone Receptor-Positive Breast Cancer
Sales Forecast by 2032: $2 billion
• Atacicept
Manufacturer: Vera Therapeutics
Indications: IgA Nephropathy
Sales Forecast by 2032: $1.7 billion
